Floatz logo

Nanrilkefusp Alfa

Mesothelioma

SOTIO Biotech AGPhase 1Dormant
D
23/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
8/ 100
Competitive Position
73/ 100

Competitive context

56 Active assets in the Mesothelioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
Orion Corporation, Orion Pharma
Phase 2B
Fludarabine
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Genmab
Phase 2B
18f-fspg
Andrei Iagaru
Phase 2B

View all 50 →

Same molecule, other indications

Nanrilkefusp Alfa is also rated in:

non-small cell lung carcinomaDormant
D
Indicative ·
30 / 100
View asset →
skin squamous cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →
hepatocellular carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →